A million-dollar collaboration between nano-drug company Starpharma and diagnostics specialist PanBio Ltd has come unstuck. [ + ]

Cryosite, a Sydney-based biotechnology service company that stores frozen biological material, is going public. [ + ]

Bumper year, 2003 - it's the 50th anniversary of the Watson and Crick's now famous paper on the structure of the DNA molecule. [ + ]

Biota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million. [ + ]

Europe risks being left behind in the biotechnology sector unless it finds a way to address public fears about genetically modified organisms, a top European Union official has warned.

Australian scientists have launched a second-generation probe described as the biggest advance in microscopy since the electron microscope.

The success of a bioinformatics conference in Hong Kong in January has led to the establishment of three similar conferences in the Asia-Pacific region. [ + ]

A new network for the medical device industry is gearing up for launch. [ + ]

Plant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government. [ + ]

Changes to Australian patent laws from April 1 will make filing harder, but will also bring the country more into line with US and European patent laws. [ + ]

South Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest. [ + ]

Victoria's government has backed stem cell research despite its existing ban on embryonic cell studies. [ + ]

Drug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program. [ + ]

Australian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago. [ + ]

Dental research group SDI has reported a half-yearly jump in profits and sales on the back of its suite of aesthetic and alloy restorative products. [ + ]